Navigation Links
Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/26/2008

o-treat pathogens. Introduced more than 50 years ago, tetracyclines remain among the most commonly used antiinfective agents to combat bacterial infections. However, the emergence of resistance has curtailed their effectiveness in certain infections. Paratek has utilized its expertise to create AMC compounds, such as PTK 0796, that retain the appealing safety and spectrum of activity of the tetracyclines while overcoming tetracycline and multi-drug resistance.

Representing one of the top therapeutic categories, the antibiotics market generates worldwide sales of over $26 billion, despite the availability of low-priced generic products for many infections. In recent years, eight antibiotics have attained annual sales of more than $1 billion each. The growing medical problem of drug-resistant bacteria presents a new and expanding market opportunity. Bacterial resistance is causing many of the current antibiotics to lose efficacy, while the pipeline of replacement products that target antibiotic resistance is remarkably thin.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance. Paratek's lead compound, PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). Oral and IV formulations of PTK 0796 were compared to Zyvox (R) in a recently completed Phase 2 clinical study in complicated skin and skin structure infections (cSSSIs). In addition to PTK 0
'/>"/>

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
2. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
3. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Zargis Medical Corp., a majority-owned subsidiary of Speedus ... from Siemens Corporate Research (NYSE: SI ... its award-winning Zargis Cardioscan(TM) system on Amazon.com, America,s ... Bluetooth®-enabled electronic stethoscope were jointly named Popular ... the Year." Cardioscan is the world,s first ...
(Date:12/14/2009)... Gibraltar Associates, a leading public ... domestic communications and issues management, today announced ... PositiveID Corporation (Nasdaq: PSID ) to ... of record. Gibraltar Associates will conduct media ... the Company on its public relations programs. ...
(Date:12/14/2009)... GeoInvesting.com, we have been tracking Tianyin Pharmaceuticals (NYSE Amex: ... hang up had been with the potential dilution from ... income guidance of $11.3 million represents a 43.0% increase ... million, the increase in shares poses some uncertainty regarding ... the share price and the Treasury method of accounting ...
Breaking Medicine Technology:Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2Morehead Presents Webinar on 26apos 3BHe Said 26amp 3B 238230 3BShe Said 3A How Gender Differences Impact Physician Engagement 26apos 3B 55447 1Morehead Presents Webinar on 26apos 3BHe Said 26amp 3B 238230 3BShe Said 3A How Gender Differences Impact Physician Engagement 26apos 3B 55447 2Slogan Contest Educates Young Baseball and Softball Players About the Dangers of Tobacco Use 55445 1Slogan Contest Educates Young Baseball and Softball Players About the Dangers of Tobacco Use 55445 2MN Community Measurement Brings Cost and Quality Information Together For Consumers 55443 1MN Community Measurement Brings Cost and Quality Information Together For Consumers 55443 2MN Community Measurement Brings Cost and Quality Information Together For Consumers 55443 3
(Date:12/14/2009)... variants seen in one gene, researchers say , , MONDAY, ... a dozen genetic variants in a single gene linked ... School of Medicine in St. Louis analyzed the DNA ... failure, and identified 129 variants in four genes that ... 1,117 whites with heart failure and 625 healthy whites ...
(Date:12/14/2009)... from common CT procedures vary widely and are higher than generally ... new study led by University of California, San Francisco (UCSF) ... ... December 14, 2009 -- Radiation doses from common CT procedures vary ... risk for cancer, according to a new study led by University ...
(Date:12/14/2009)... Calif., Dec. 14 Grubb & Ellis Healthcare REIT ... authorized a daily distribution to stockholders of record as of ... commencing on Jan. 1, 2010 and ending on Feb. 28, ... days in the calendar year and will be equal to ... price of $10.00 per share. These distributions will be ...
(Date:12/14/2009)... benefited men whose disease had been treated, hadn,t spread, ... Exercise appears to reduce the risk of death in ... which began in January 1986, included 668 men who,d ... III colon cancer that had not spread (nonmetastatic cancer). ... asked them about any new cancer and disease diagnoses, ...
(Date:12/14/2009)... San Diego School of Medicine and Osaka University in ... liver damage, including inflammation, fibrosis and cancer. The findings ... TAK1, works could lead to new insights into the ... appears to be a master regulator of liver function," ... Dean of the UC San Diego School of Medicine. ...
Breaking Medicine News(10 mins):Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Scientists uncover protective mechanism against liver cancer 2
... Nonprofit Organization, Carolyn,s Compassionate Children gives cancer, ... hope of attending college, BOSTON, June 7 ... senior and cancer survivor Leanna,Elizalde with a $2,500 ... High School,s graduation ceremony Saturday. Alex Oden, 20, ...
... to Acquire, Instantaneous, Non-Stitched Full-Volume Images of the Heart in ... ... TORONTO, June 7 Siemens Healthcare, (http://www.usa.siemens.com/healthcare ) unveils the ... to acquire,non-stitched, real-time full-volume 3D images of the heart in one ...
... glucose levels is key for most diabetics , , FRIDAY, June ... of aggressively lowering blood sugar in people with type 2 ... a 21 percent reduced risk for kidney disease, ... risk of death. , However, the first study found no ...
... Over time, players less able to transfer weight on shots, so ... News) -- If you walk rather than ride a cart when ... and maybe more strokes to your score, a new report suggests. ... change for the worse, causing the player to hit the ball ...
... and Research Assistant Professor Hitoshi Inada (National Institute for ... receptor, PKD1L3-PKD2L1 channel complex, could be activated by acid ... acid stimulus. They call this new type of response ... finding in an international journal, EMBO reports, on June ...
... CRGN ) announced today that Dr. Timothy Shannon, President ... Needham &,Company Biotechnology and Medical Technology Conference on Wednesday, ... is being held at the,New York Palace Hotel in ... of the presentation will be available from the,Investor Relations ...
Other Medicine News:Health News:Nonprofit Organization Dedicated to Helping Young Adult Cancer Survivors Raises $4500 for Leanna Elizalde 2Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 2Health News:Siemens' New Ultrasound Platform Revolutionizes the Paradigm of Echocardiography 3Health News:Studies Differ on Benefits of Aggressive Blood Sugar Control 2Health News:Studies Differ on Benefits of Aggressive Blood Sugar Control 3Health News:Studies Differ on Benefits of Aggressive Blood Sugar Control 4Health News:Walking Golf Course Affects Swing, Performance 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: